VVD-130037 for Advanced Cancers

Recruiting in Palo Alto (17 mi)

+14 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Vividion Therapeutics, Inc.

Must not be taking: Anti-epileptics

Disqualifiers: Seizures, CNS metastases, Hypertension, others

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a new drug, VVD-130037, for safety and effectiveness in patients with advanced solid tumors. It will study how the drug moves through and affects the body, and whether it can help treat these tumors.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are on anti-epileptic medications, you cannot participate in this trial.

What data supports the effectiveness of the drug VVD-130037 for advanced cancers?

Research shows that combinations of drugs similar to VVD-130037, like vinorelbine and cisplatin, have been effective in treating advanced non-small cell lung cancer by inhibiting cancer cell growth and improving patient outcomes. ^{1 2 3 4 5}

What safety data exists for VVD-130037 in humans?

Dilpacimab, previously known as ABT-165, was tested in a study with 55 patients having advanced solid tumors. Common side effects included high blood pressure (60%), headache (31%), and tiredness (22%). A serious side effect was a hole in the stomach or intestine, which happened in 2 patients and led to 1 death. ^{6 7 8 9 10}

Research Team

Eligibility Criteria

This trial is for adults with advanced solid tumors who have tried all standard treatments without success. They must be relatively active (ECOG ≤1), have a confirmed diagnosis, measurable disease by RECIST v1.1, and good organ/marrow function. It's not for those with certain genetic mutations or unresolved severe side effects from past cancer treatments, heart issues, seizure risks, brain metastases/spinal compression, or uncontrolled high blood pressure.

Inclusion Criteria

My cancer is confirmed to be advanced and cannot be removed by surgery.

My organs and bone marrow are functioning well.

Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the Investigator

Exclusion Criteria

I have taken medication for seizures.

I have or had cancer spread to my brain or spinal cord.

I have a history of seizures or a condition that could lead to seizures.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants receive ascending doses of VVD-130037, either as a single agent or in combination with docetaxel or paclitaxel, in 21-day or 28-day treatment cycles

21-28 days per cycle

Multiple visits per cycle for treatment and monitoring

Dose Expansion

Participants receive VVD-130037 at the recommended dose for expansion, either as a single agent or in combination with docetaxel or paclitaxel, in 21-day or 28-day treatment cycles

Up to approximately 4 years

Regular visits for treatment and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• VVD-130037 (Other)

Trial Overview The study tests VVD-130037 to see its safety and how it affects the body and tumor growth in patients with advanced solid tumors. This first-in-human trial will also look at how the drug moves through and out of the body (pharmacokinetics) and what it does to the body (pharmacodynamics).

Participant Groups

Group I: Part 2 (Dose Expansion): VVD-130037 and Paclitaxel Combination Therapy Experimental Treatment 2 Interventions

Participants will receive VVD-130037 at the RDE, orally, once or twice daily along with paclitaxel IV infusion administered on Days 1, 8, and 15 of each 28-day treatment cycle during Part 2.

Group II: Part 2 (Dose Expansion): VVD-130037 and Docetaxel Combination Therapy Experimental Treatment 2 Interventions

Participants will receive VVD-130037 at the RDE, orally, once or twice daily along with docetaxel IV infusion administered once every 3 weeks in 21-day treatment cycles during Part 2.

Group III: Part 2 (Dose Expansion): VVD-130037 Single Agent Experimental Treatment 1 Intervention

Participants will receive VVD-130037 at the recommended dose for expansion (RDE), orally, once or twice daily in 21-day treatment cycles during Part 2.

Group IV: Part 1 (Dose Escalation): VVD-130037 and Paclitaxel Combination Therapy Experimental Treatment 2 Interventions

Participants will receive ascending doses of VVD-130037, orally, once or twice daily along with paclitaxel IV infusion administered on Days 1, 8, and 15 of each 28-day treatment cycle during Part 1.

Group V: Part 1 (Dose Escalation): VVD-130037 and Docetaxel Combination Therapy Experimental Treatment 2 Interventions

Participants will receive ascending doses of VVD-130037, orally, once or twice daily along with docetaxel intravenous (IV) infusion administered once every 3 weeks in 21-day treatment cycles during Part 1.

Group VI: Part 1 (Dose Escalation): VVD-130037 Single Agent Experimental Treatment 1 Intervention

Participants will receive ascending doses of VVD-130037, orally, once or twice daily in 21-day treatment cycles during Part 1.

Who Is Running the Clinical Trial?

Vividion Therapeutics, Inc.

Lead Sponsor

Trials

3

Recruited

780+

Findings from Research

In a study of 76 patients with advanced non-small-cell lung cancer (NSCLC), the chemotherapy combination of vinorelbine, ifosfamide, and cisplatin resulted in a 51% overall response rate, indicating its potential effectiveness in treating this condition.

The treatment was associated with manageable toxicities, primarily leukopenia, with 26% of cycles experiencing severe neutropenia, suggesting that while the regimen is effective, careful monitoring for side effects is necessary.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Baldini, E., Tibaldi, C., Chella, A., et al.[2020]

The combination of navelbine (NVB) and cisplatin (CDDP) showed a synergistic effect on killing lung adenocarcinoma cells when NVB was administered before CDDP, indicating a potentially more effective treatment strategy compared to using vindesine (VDS) with CDDP.

Both NVB and VDS caused cell cycle arrest in the G2M phase, while CDDP led to S phase accumulation, suggesting different mechanisms of action that could be exploited for enhanced therapeutic effects in cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. Gomi, K., Ohno, H., Nomura, K., et al.[2019]

The neoadjuvant chemotherapy regimen of ifosfamide, cisplatin, and etoposide (VIP) followed by concomitant thoracic radiotherapy was found to be feasible for treating locally advanced non-small cell lung cancer (NSCLC), with a 61% objective response rate by the end of radiotherapy.

However, the treatment was associated with significant toxicities, including myelosuppression and acute esophagitis, leading to hospital readmissions for 23 patients, which raises concerns about the safety and limits the further development of this aggressive treatment approach.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. Pujol, JL., Lafontaine, T., Quantin, X., et al.[2019]

VM 26 and VP 16-213, epipodophyllotoxin derivatives entering phase III studies, show significant effectiveness against small-cell lung carcinoma and other cancers, particularly in the late S and G2 phases of the cell cycle.

VP 16-213 has demonstrated notable clinical activity in various cancers, including Hodgkin's disease and non-Hodgkin lymphomas, suggesting it may be prioritized over VM-26 for further development and research.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review. Nissen, NI., Dombernowsky, P., Hansen, HH., et al.[2019]

A series of novel VEGFR-2 inhibitors were discovered, with compound 23 showing superior antiproliferative effects compared to FDA-approved drugs like sorafenib and sunitinib across nine tumor types.

Compound 23 demonstrated high potency against drug-resistant cancer cell lines, suggesting it could be a promising treatment option for various cancers, including leukemia, NSCLC, colon, ovarian, and breast cancer, while maintaining a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. Zhang, Y., Chen, Y., Zhang, D., et al.[2019]

The maximum tolerated dose (MTD) of veliparib when combined with pegylated liposomal doxorubicin (PLD) and carboplatin for treating recurrent ovarian cancer is determined to be 80 mg taken twice daily, with myelosuppression identified as a dose-limiting toxicity (DLT).

In patients receiving the combination of veliparib and bevacizumab, 75% experienced DLTs, including severe thrombocytopenia and hypertension, indicating that lower doses of veliparib may be necessary when used with platinum-based therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Landrum, LM., Brady, WE., Armstrong, DK., et al.[2022]

Dilpacimab, a dual-variable domain immunoglobulin targeting DLL4 and VEGF pathways, showed an acceptable safety profile in a phase I study with 55 patients, where common side effects included hypertension (60%) and headache (30.9%).

The study established a recommended phase II dose of 3.75 mg/kg, with preliminary efficacy showing a partial response in 10.9% of patients, particularly in ovarian cancer, indicating potential clinical activity in advanced solid tumors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Gordon, MS., Nemunaitis, J., Barve, M., et al.[2023]

References

1. England pubmed.ncbi.nlm.nih.gov

Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. [2020]

2. Japan pubmed.ncbi.nlm.nih.gov

Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. [2019]

3. United States pubmed.ncbi.nlm.nih.gov

Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. [2019]

4. Germany pubmed.ncbi.nlm.nih.gov

The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review. [2019]

5. Italy pubmed.ncbi.nlm.nih.gov

Cisplatin plus continuous infusion vinorelbine for the treatment of advanced non-small cell lung cancer: a phase I-II study. [2019]

6. Germany pubmed.ncbi.nlm.nih.gov

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. [2013]

7. United States pubmed.ncbi.nlm.nih.gov

Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. [2022]

8. United States pubmed.ncbi.nlm.nih.gov

Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. [2019]

9. United States pubmed.ncbi.nlm.nih.gov

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. [2023]